NasdaqGM:ALVOBiotechs
Are Expanded Sandoz Biosimilar Deals Quietly Reframing Alvotech’s Partnership Strategy and Scale Ambitions (ALVO)?
Alvotech recently reported positive top-line results from a pharmacokinetic study for AVT80, its subcutaneous biosimilar candidate to Entyvio, and also finalized new global patent settlements and commercial entry timelines for its aflibercept biosimilar AVT06.
In parallel, Alvotech entered expanded supply and commercialization agreements with Sandoz across Canada, Australia and New Zealand, signalling a broader role as a development and manufacturing partner for multiple biosimilars.
We’ll...